Satavaptan
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number | 185913-78-4 |
PubChem (CID) | 9810773 |
ChemSpider | 32699105 |
UNII | AJS8S3P31H |
ECHA InfoCard | 100.211.853 |
Chemical and physical data | |
Formula | C33H45N3O8S |
Molar mass | 643.789 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Satavaptan (INN; codenamed SR121463, planned tradename Aquilda) is a vasopressin-2 receptor antagonist[1] undergoing research for the treatment of hyponatremia. It is also being studied for the treatment of ascites.[2]
It was developed by Sanofi-Aventis. As of 2008, it is under regulatory review in the European Union.
References
- ↑ Soupart A, Gross P, Legros JJ, et al. (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clin J Am Soc Nephrol. 1 (6): 1154–1160. doi:10.2215/CJN.00160106. PMID 17699341.
- ↑ Ginès P; Wong F; Watson H; Milutinovic S; Ruiz Del Arbol L; Olteanu D (February 2008). "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial". Hepatology. 48 (1): 204–213. doi:10.1002/hep.22293. PMID 18508290.
This article is issued from Wikipedia - version of the 9/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.